William Smith, MD
Internal Medicine · Chattanooga, TNNPI 1891769212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $248 and has fallen 58.8% since, to $102 in 2025.
Across 49 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$189
- Abbott$175
- GSK$91
- AbbVie$58
- Boston Scientific$52
- Antares Pharma, Inc.$39
- plus $206 from 11 others
Across 32 payments — averaging $511.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$16K
What the payments were for
- Food & beverage$811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $189 |
| Abbott | 9 | $175 |
| GSK | 5 | $91 |
| AbbVie | 3 | $58 |
| Boston Scientific | 2 | $52 |
| Antares Pharma, Inc. | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Merck | 1 | $17 |
| Pfizer | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| ALON Medical Technology | 1 | $15 |
| Vapotherm Inc | 1 | $13 |
How this compares
$811 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $133,767 |
| FarxigaDapagliflozin Propanediol | 113 | $94,505 |
| EliquisApixaban | 77 | $90,576 |
| JanuviaSitagliptin Phosphate | 51 | $61,444 |
| JardianceEmpagliflozin | 30 | $33,982 |
| XifaxanRifaximin | 11 | $33,925 |
| XareltoRivaroxaban | 47 | $33,520 |
| MounjaroTirzepatide | 21 | $23,702 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $17,771 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $16,382 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,517 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,267 |
| TrulicityDulaglutide | 12 | $11,492 |
| LinzessLinaclotide | 14 | $11,310 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $7,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $15 | $133,767120 claims |
| PfizerEliquis | $17 | $90,57677 claims |
| MerckJanuvia, Janumet | $17 | $79,21566 claims |
| Lilly USA, LLCMounjaro, Trulicity | $25 | $35,19433 claims |
| Boehringer IngelheimJardiance | $17 | $33,98230 claims |
| AbbVieLinzess, Lumigan | $58 | $16,40625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Chattanooga
- Maighan SeagroveChattanooga$78K
- Carlton VollbergChattanooga$30K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- Eugene RyanChattanooga$26K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.